Early and delayed puberty among Iranian children with obesity

Reihaneh Mohsenipour1, Farzaneh Abbasi1, Aria Setoodeh1

  • 1Growth and Development Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Minerva Endocrinology
|August 4, 2020
PubMed

Insights

Childhood obesity in Tehran is linked to puberty delays in boys, not girls. Higher birth weight also correlates with earlier obesity onset, highlighting the need for early prevention strategies.

Area of Science:

  • Pediatric Endocrinology
  • Public Health
  • Childhood Obesity Research

Background:

  • Childhood obesity is a growing concern globally and in Iran.
  • Weight gain in children has been hypothesized to disrupt normal puberty onset.
  • Understanding puberty disturbances in obese children is crucial for health interventions.

Purpose of the Study:

  • To investigate the prevalence of puberty disturbances in obese children in Tehran, Iran.
  • To identify risk factors associated with puberty disturbances in this population.

Main Methods:

  • A cross-sectional study was conducted with 168 obese children in Tehran.
  • Data were collected between March 2018 and February 2019.
  • Inclusion criteria included a Body Mass Index (BMI) percentile above 95%.

Main Results:

  • No significant difference in early puberty was observed between males and females (P=0.098).
  • Delayed puberty was significantly more prevalent in obese boys compared to girls (P=0.029).
  • Higher birth weight was associated with an earlier onset of childhood obesity (P=0.044).

Conclusions:

  • Obesity in girls was not associated with early puberty, but obese boys experienced delayed puberty.
  • Higher birth weight is a predictor for the earlier development of childhood obesity.
  • Findings underscore the importance of preventive interventions for childhood obesity and its associated pubertal disturbances.
Abstract

Related Concept Videos

Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
1.1K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.0K
Socioemotional Experience and Gender Development01:30

Socioemotional Experience and Gender Development

Social-emotional experiences and cultural influences play significant roles in shaping gender development. During middle childhood, from ages 6 to 11, peer groups become dominant in reinforcing gender norms. Children in this age group often align with same-gender peer groups, which actively encourage behaviors that conform to traditional gender roles. For instance, boys may be discouraged from engaging in activities perceived as feminine, reinforcing culturally dictated norms about masculinity...
201
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
99
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
144
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
141